吉西他滨联合顺铂治疗老年晚期非小细胞肺癌临床观察  

Clincal analysis of gemcitabine plus cisplatin for patients with eldly advanced non-small cell lung cancer

作　　者：孙宏伟[1] 颚颖[1] 高红[1] 高雅苓[1] 

机构地区：[1]辽宁省肿瘤医院内一科,辽宁沈阳110042

出　　处：《中华肿瘤防治杂志》2010年第7期541-542,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了评价吉西他滨联合顺铂进行适当剂量调整后,在治疗老年晚期非小细胞肺癌患者中的疗效和毒副反应,对病理确诊的112例晚期老年NSCLC患者采用GP方案化疗。吉西他滨800mg/m2,d1,d8,静脉滴入;顺铂25mg/m2,d1～d3,静脉滴入。21d为1个周期,至少化疗2个周期后评价疗效。4例完全缓解(CR),33例部分缓解(PR),24例稳定(SD),51例进展(PD),总有效率为33.0%。其中腺癌有效率为31.0%,鳞癌有效率为37.0%,腺癌、鳞癌两组之间比较差异无统计学意义,P>0.05。初治有效率为40.0%,复治有效率为19.4%,两组疗效比较差异有统计学意义,P<0.05。吉西他滨联合顺铂方案治疗老年非小细胞肺癌疗效较好,且毒副反应轻,对于老年、体能状态评分(PS)不佳的晚期复发进展NSCLC患者值得推荐。The objective of this study was to evalute the efficacy and toxicity of gemcitabine and cisplatin in eldly advanced non-small cell lung cancer.All the 112 patients with advanced non-small lung cancer received gemcitabine and cisplatin （gemcitabine 800 mg/m2,d1,d8,cisplatin 25 mg/m2,d1-d3）,intravenous injection,21 d as 1 cycle and for 2 cycles at least.All the patients were evaluable for response.Four patients achiieved CR,33 PR,24 SD,and 51 PD,with a total response rate （RR） of 33.0%.Adenocarcinoma patients efficacy were 31.0%,squamous celll carcinoma patients were 37.0%,There was no significant difference between the two groups （P0.05）.Previously untreated efficacy were 40.0%,previously treated efficacy were 19.4%.There was a significant difference between the two groups （P0.05）.In conclusion,gemcitabine plus cisplatin shows a good response and tolerance in eldly patients with advanced non-small cell lung cancer.

关 键 词：癌 非小细胞肺/药物疗法 药物疗法 联合 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]